Table 3. Associations between CYP2E1 polymorphisms and gastric cancer risk.
| Polymorphism of CYP2E1 | Case | Control | Crude OR (95% CI) | Adjusteda OR (95% CI) | ||
| No. | % | No. | % | |||
| PstI genotypes | ||||||
| C1C1 | 348 | 68.2 | 374 | 73.3 | 1.00 | 1.00 |
| C1C2 | 128 | 25.1 | 119 | 23.3 | 1.31 (0.98–1.74) | 1.35 (1.01–1.80) |
| C2C2 | 34 | 6.7 | 17 | 3.3 | 2.21 (1.21–4.03) | 2.15 (1.18–3.94) |
| C1C2+C2C2 | 162 | 31.8 | 136 | 26.7 | 1.42 (1.09–1.86) | 1.49 (1.13–1.96) |
| DraI genotypes | ||||||
| TT | 334 | 65.5 | 318 | 62.3 | 1.00 | 1.00 |
| TA | 131 | 25.7 | 160 | 31.4 | 0.78 (0.59–1.03) | 0.76 (0.58–1.01) |
| AA | 45 | 8.8 | 32 | 6.3 | 1.33 (0.83–2.16) | 1.34 (0.83–2.17) |
| TA+AA | 176 | 34.5 | 192 | 37.6 | 0.86 (0.66–1.11) | 0.85 (0.65–1.10) |
| PstI and DraI genotypes | ||||||
| C1C1/TT | 212 | 41.6 | 233 | 45.7 | 1.00 | 1.00 |
| C1C2/TA | 83 | 16.3 | 77 | 15.1 | 1.20 (0.83–1.72) | 1.13 (0.79–1.63) |
| C2C2/AA | 26 | 5.1 | 11 | 2.2 | 2.62 (1.26–5.44) | 2.66 (1.27–5.57) |
a
Adjusted for sex, age and smoking habit.